药物对比
Saxagliptin vs Ertugliflozin
Saxagliptin（口服DPP-4抑制剂）vs Ertugliflozin（口服SGLT2抑制剂）治疗2型糖尿病。比较作用机制、低血糖、体重、心血管获益和安全性。
此页面暂无可用的对比维度。
临床背景
This comparison arises when selecting an oral add-on agent for type 2 diabetes between a DPP-4 inhibitor and an SGLT2 inhibitor.
结论
Both lower blood sugar in type 2 diabetes but differ in class effects, so the better choice depends on patient comorbidities and risk factors.
全部药物对比